Search clinical trials for: AzaSite (azithromycin ophthalmic solution)

Total 1478 results

Beijing Tongren Hospital
Zhuhai Essex Bio-Pharmaceutical Company Limited; Panacea Technologies

Unknown

Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

Bacterial Conjunctivitis

China
Philadelphia Eye Associates
Merck Sharp & Dohme LLC; Thomas Jefferson University

Withdrawn

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Meibomian Gland Dysfunction

United States
Merck Sharp & Dohme LLC

Terminated

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Posterior Blepharoconjunctivitis

United States
Merck Sharp & Dohme LLC

Completed

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Bacterial Infections | Eye Infections | Cataract Extraction

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Blepharitis

United States
Merck Sharp & Dohme LLC

Terminated

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)

Blepharitis
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Hanlim Pharm. Co., Ltd.

Completed

A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects

Healthy Subject
Merck Sharp & Dohme LLC

Completed

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Bacterial Infections | Eye Infections

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

Contact Lens Dry Eye

United States
Mitotech, SA
ORA, Inc.

Completed

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Keratoconjunctivitis Sicca

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

Blepharitis

United States
Beijing Tongren Hospital
Grand Pharmaceutical (China) Co., Ltd.

Unknown

Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

Pharmacokinetics

China
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Laboratorios Sophia S.A de C.V.

Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis (PRO-118)

Conjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic Conjunctivitis

Mexico
ORA, Inc.
Palatin Technologies, Inc

Completed

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

Dry Eye Disease

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Herantis Pharma Plc.
ORA, Inc.

Completed

Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease

Dry Eye Disease

Canada
Mimetogen Pharmaceuticals USA, Inc.

Active, not recruiting

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye Syndromes | Dry Eye Disease | Kerato Conjunctivitis Sicca

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Dry Eye

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Keratoconjunctivitis Sicca

United States
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
OcuTerra Therapeutics, Inc.

Completed

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Mimetogen Pharmaceuticals USA, Inc.

Completed

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Aerie Pharmaceuticals

Completed

Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
University of Louisville

Completed

Lipids of the Human Tear Film and Their Effect on Tear Stability

Blepharitis

United States
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
VivaVision Biotech, Inc

Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaucoma, Open-Angle

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Myopia

Singapore
Santen Pharmaceutical Asia Pte. Ltd.

Recruiting

Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NOPAPS)

Ocular Hypertension | Primary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma, Suspect

Korea, Republic of

3

Subscribe